Suppr超能文献

验证一种移植后慢性肺移植物功能障碍分类系统。

Validation of a post-transplant chronic lung allograft dysfunction classification system.

机构信息

Lung Transplant Unit, Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), Katholieke Universiteit Leuven, Leuven, Belgium.

Departments of Imaging & Pathology, Katholieke Universiteit Leuven, Leuven, Belgium.

出版信息

J Heart Lung Transplant. 2019 Feb;38(2):166-173. doi: 10.1016/j.healun.2018.09.020. Epub 2018 Oct 4.

Abstract

BACKGROUND

Long-term survival after lung transplantation (LTx) is hampered by chronic lung allograft dysfunction (CLAD). Our study evaluated the prevalence and prognostic importance of obstructive and restrictive CLAD phenotypes, with or without an identifiable underlying cause, to validate the recently proposed classification system for CLAD.

METHODS

Data for patients who underwent LTx between 2004 and 2015 with a minimal survival of 180 days post-LTx were retrospectively collected. Double LTx patients with CLAD (defined as a persistent forced expiratory volume in 1 second decline of ≥ 20% compared with baseline) were subsequently classified according to obstructive (forced expiratory volume in 1 second /forced vital capacity [FVC] < 70%, total lung capacity > 90%, and FVC > 80%) or restrictive (total lung capacity ≤ 90% or FVC ≤ 80%) pulmonary function and to the presence of an unknown (bronchiolitis obliterans syndrome [BOS]/restrictive allograft syndrome [RAS]) or known (non-BOS/non-RAS) underlying cause.

RESULTS

After a median of 3.2 years, CLAD developed in 39% of double LTx patients (n = 219), of which 20% (n = 43) had an identifiable cause. Survival was worse in patients with restrictive CLAD (26%) compared with obstructive CLAD (64%; p < 0.0001). Non-BOS patients suffered from inferior survival compared with BOS patients (p = 0.0016), whereas there was no significant difference in survival between RAS and non-RAS (p = 0.17). Patients who evolved from an obstructive (BOS) to a restrictive (RAS) phenotype (10%) experienced better survival than RAS patients and a worse outcome compared with BOS patients (p < 0.0001).

CONCLUSIONS

Given the differences in outcome, accurate diagnosis of CLAD phenotypes is important, because this helps to inform patients about their prognosis, to reveal underlying pathogenesis, to identify homogenous patient populations for clinical trials, and to guide future therapeutic approaches.

摘要

背景

肺移植(LTx)后的长期存活率受到慢性肺移植物功能障碍(CLAD)的阻碍。本研究评估了有或无明确潜在病因的阻塞性和限制性 CLAD 表型的流行率和预后重要性,以验证最近提出的 CLAD 分类系统。

方法

回顾性收集了 2004 年至 2015 年期间接受 LTx 且术后至少存活 180 天的患者的数据。随后,对出现 CLAD(定义为与基线相比,持续 1 秒用力呼气量下降≥20%)的双肺移植患者根据阻塞性(1 秒用力呼气量/用力肺活量[FVC]<70%,总肺容量>90%,FVC>80%)或限制性(总肺容量≤90%或 FVC≤80%)肺功能,并根据有无未知(闭塞性细支气管炎综合征[BOS]/限制性移植物综合征[RAS])或已知(非-BOS/非-RAS)潜在病因进行分类。

结果

中位随访 3.2 年后,219 例双肺移植患者(39%)发生 CLAD,其中 20%(43 例)有明确病因。与阻塞性 CLAD(64%)相比,限制性 CLAD 患者的生存率更差(26%;p<0.0001)。非-BOS 患者的生存率低于 BOS 患者(p=0.0016),而 RAS 与非-RAS 患者的生存率无显著差异(p=0.17)。从阻塞性(BOS)转变为限制性(RAS)表型(10%)的患者的生存率优于 RAS 患者,而预后差于 BOS 患者(p<0.0001)。

结论

鉴于预后存在差异,准确诊断 CLAD 表型很重要,因为这有助于向患者告知预后,揭示潜在发病机制,为临床试验确定同质患者人群,并指导未来的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验